Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
spinal muscular atrophy
Pharma
FDA probes Novartis’ Zolgensma gene therapy over cancer risks
The FDA also flagged two recent reports of other gene therapy candidates where AAV vector integration drove tumor formation.
Angus Liu
Nov 9, 2026 11:14am
Novartis confirms several new tumor cases in Zolgensma patients
Nov 6, 2026 9:59am
Scholar Rock scores its first FDA approval for SMA treatment
Sep 14, 2026 10:37am
Novo’s Catalent plant ditched in FDA refiling of SMA drug
Aug 10, 2026 10:06am
Biogen launches ‘Ready for More’ HD Spinraza campaign
Jun 26, 2026 8:17am
Novartis teams with Becoming rentABLE for its new SMA campaign
Jun 25, 2026 8:38am